Thursday, January 04, 2024 7:21:06 AM
Published: Jan. 4, 2024 at 7:06 a.m. ET
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
| Source: Novo Nordisk A/S
Share
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management
Cellarity collaboration will build upon initial work and engage the company’s platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering
Novo Nordisk will reimburse R&D costs and each company and Flagship’s Pioneering Medicines are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties
Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc.
https://www.globenewswire.com/news-release/2024/01/04/2803788/0/en/Novo-Nordisk-enters-into-research-collaborations-with-Omega-Therapeutics-and-Cellarity-on-novel-treatment-approaches-for-cardiometabolic-diseases.html
Volume: | 502,057 |
Day Range: | 0.503 - 0.551 |
Bid: | 0.5005 |
Ask: | 0.5087 |
Last Trade Time: | 5:36:55 PM EST |
Total Trades: | 1,309 |
Recent OMGA News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2025 10:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 09:47:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2024 10:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2024 10:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2024 09:10:05 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2024 09:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 11:31:30 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 11:27:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2024 11:09:18 PM
- Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/14/2024 09:05:00 PM
- Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence • PR Newswire (US) • 10/23/2024 12:00:00 PM
- Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings • GlobeNewswire Inc. • 10/15/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:00:08 PM
- Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors • PR Newswire (US) • 10/03/2024 12:00:00 PM
- Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications • GlobeNewswire Inc. • 09/17/2024 11:00:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:01:07 PM
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research • GlobeNewswire Inc. • 08/14/2024 11:00:08 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:03:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:02:33 AM
- Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/06/2024 11:00:09 AM
- Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner • PR Newswire (US) • 08/06/2024 10:30:00 AM
- Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors • GlobeNewswire Inc. • 06/24/2024 11:00:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:57:45 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/30/2024 09:10:10 PM
- Omega Therapeutics To Participate In Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:59 AM
FEATURED Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM